VBI Vaccines Receives US FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines Inc. announced that the US FDA granted Orphan Drug Designation for VBI-1901, a bivalent gB/pp65 immunotherapeutic vaccine candidate for the treatment of glioblastoma.